MD4508C1 - Hemifumarat de tenofovir alafenamidă şi utilizările sale medicale - Google Patents

Hemifumarat de tenofovir alafenamidă şi utilizările sale medicale

Info

Publication number
MD4508C1
MD4508C1 MDA20140011A MD20140011A MD4508C1 MD 4508 C1 MD4508 C1 MD 4508C1 MD A20140011 A MDA20140011 A MD A20140011A MD 20140011 A MD20140011 A MD 20140011A MD 4508 C1 MD4508 C1 MD 4508C1
Authority
MD
Moldova
Prior art keywords
tenofovir alafenamide
medical uses
alafenamide hemifumarate
hemifumarate
phenoxyphosphinyl
Prior art date
Application number
MDA20140011A
Other languages
English (en)
Russian (ru)
Other versions
MD20140011A2 (ro
MD4508B1 (ro
Inventor
Дажан ЛИУ
Б Ши
Ван
Хун Чю ЮЙ Ричард
Original Assignee
Gilead Sciences, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46785793&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MD4508(C1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gilead Sciences, Inc. filed Critical Gilead Sciences, Inc.
Publication of MD20140011A2 publication Critical patent/MD20140011A2/ro
Publication of MD4508B1 publication Critical patent/MD4508B1/ro
Publication of MD4508C1 publication Critical patent/MD4508C1/ro

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Prezenta invenţie se referă la o formă de hemifumarat de 9-[(R)-2-[[(S)-[[(S)-1-(izopropoxicarbonil)etil]amino]fenoxifosfinil]metoxi]propil] adenină (tenofovir alafenamidă) cu formula (I) şi la terapia antivirală folosind (I), de exemplu, în tratamentul infecţiilor cu HIV şi HBV.
MDA20140011A 2011-08-16 2012-08-15 Hemifumarat de tenofovir alafenamidă şi utilizările sale medicale MD4508C1 (ro)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161524224P 2011-08-16 2011-08-16
PCT/US2012/050920 WO2013025788A1 (en) 2011-08-16 2012-08-15 Tenofovir alafenamide hemifumarate

Publications (3)

Publication Number Publication Date
MD20140011A2 MD20140011A2 (ro) 2014-05-31
MD4508B1 MD4508B1 (ro) 2017-08-31
MD4508C1 true MD4508C1 (ro) 2018-03-31

Family

ID=46785793

Family Applications (1)

Application Number Title Priority Date Filing Date
MDA20140011A MD4508C1 (ro) 2011-08-16 2012-08-15 Hemifumarat de tenofovir alafenamidă şi utilizările sale medicale

Country Status (41)

Country Link
US (2) US8754065B2 (ro)
EP (3) EP3070088A1 (ro)
JP (5) JP5651275B2 (ro)
KR (1) KR101612642B1 (ro)
CN (2) CN103732594A (ro)
AP (1) AP3639A (ro)
AR (1) AR087546A1 (ro)
AU (1) AU2012296622C1 (ro)
BR (1) BR112014003420B1 (ro)
CA (1) CA2845553C (ro)
CL (1) CL2014000370A1 (ro)
CO (1) CO6880063A2 (ro)
CR (1) CR20140072A (ro)
CY (1) CY1118385T1 (ro)
DK (1) DK2744810T4 (ro)
EA (1) EA027768B1 (ro)
EC (1) ECSP14013206A (ro)
ES (1) ES2608871T5 (ro)
FI (1) FI2744810T4 (ro)
HK (1) HK1199026A1 (ro)
HR (1) HRP20161696T4 (ro)
HU (1) HUE031253T2 (ro)
IL (2) IL230949A (ro)
IN (1) IN2014DN01012A (ro)
LT (1) LT2744810T (ro)
MA (1) MA35350B1 (ro)
MD (1) MD4508C1 (ro)
ME (1) ME02612B (ro)
MX (1) MX336627B (ro)
PE (1) PE20141328A1 (ro)
PL (1) PL2744810T5 (ro)
PT (1) PT2744810T (ro)
RS (1) RS55353B2 (ro)
SG (1) SG2014011548A (ro)
SI (1) SI2744810T2 (ro)
SM (1) SMT201600476B (ro)
TW (1) TWI516499B (ro)
UA (1) UA115311C2 (ro)
UY (1) UY34262A (ro)
WO (1) WO2013025788A1 (ro)
ZA (1) ZA201400582B (ro)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8754065B2 (en) 2011-08-16 2014-06-17 Gilead Sciences, Inc. Tenofovir alafenamide hemifumarate
CN107266498B (zh) 2011-10-07 2023-10-03 吉利德科学公司 制备抗病毒核苷酸类似物的方法
KR20140119177A (ko) * 2012-02-03 2014-10-08 길리애드 사이언시즈, 인코포레이티드 바이러스 감염의 치료에 사용하기 위한 테노포비르 알라페나미드 헤미푸마레이트 및 코비시스타트를 포함하는 조합 요법
WO2015040640A2 (en) * 2013-09-20 2015-03-26 Laurus Labs Private Limited An improved process for the preparation of tenofovir alafenamide or pharmaceutically acceptable salts thereof
TWI660965B (zh) 2014-01-15 2019-06-01 美商基利科學股份有限公司 泰諾福韋之固體形式
US9463194B2 (en) 2014-02-05 2016-10-11 Gilead Sciences, Inc. Methods of treating patients co-infected with HIV and tuberculosis
CN105085571A (zh) * 2014-05-20 2015-11-25 四川海思科制药有限公司 替诺福韦艾拉酚胺复合物及其制备方法和用途
CN105646584B (zh) * 2014-11-12 2018-09-28 四川海思科制药有限公司 替诺福韦艾拉酚胺富马酸盐晶型及其制备方法和用途
CN105237571B (zh) * 2014-11-28 2018-03-09 成都苑东生物制药股份有限公司 9‑[(r)‑2‑[[(s)‑[[(s)‑1‑(异丙氧基羰基)乙基]氨基]苯氧基氧膦基]甲氧基]丙基]腺嘌呤的盐
CN104558036A (zh) * 2014-12-11 2015-04-29 杭州和泽医药科技有限公司 一种替诺福韦艾拉酚胺半反丁烯二酸盐晶型及其制备方法
RS62434B1 (sr) 2014-12-26 2021-11-30 Univ Emory Antivirusni n4-hidroksicitidin derivati
WO2016108205A1 (en) 2015-01-03 2016-07-07 Mylan Laboratories Limited Processes for the preparation of amorphous tenofovir alafenamide hemifumarate and a premix thereof
CN105669751B (zh) * 2015-03-05 2018-09-21 洛阳聚慧医药科技有限公司 非环核苷酸磷酰胺类化合物及其盐的制备以及在抗病毒方面的应用
GB201509431D0 (en) * 2015-06-01 2015-07-15 Equigerminal Sa Antiviral composition
CZ2015384A3 (cs) 2015-06-05 2016-12-14 Zentiva, K.S. Pevné formy Tenofovir alafenamidu
US9777028B2 (en) 2015-06-17 2017-10-03 Gilead Sciences, Inc. Co-crystals, salts and solid forms of tenofovir alafenamide
WO2017004244A1 (en) 2015-06-30 2017-01-05 Gilead Sciences, Inc. Pharmaceutical formulations comprising tenofovir and emtricitabine
WO2017007701A1 (en) * 2015-07-07 2017-01-12 Merck Sharp & Dohme Corp. Antiviral phosphodiamide compounds
CN107849071B (zh) 2015-08-10 2021-03-09 默沙东公司 抗病毒的β氨基酸酯膦酰二胺化合物
WO2017037608A1 (en) * 2015-08-28 2017-03-09 Laurus Labs Private Limited Solid forms of tenofovir alafenamide and salts thereof, processes for its preparation and pharmaceutical compositions thereof
SG11201802983TA (en) 2015-11-09 2018-05-30 Gilead Sciences Inc Therapeutic compositions for treatment of human immunodeficiency virus
CN106699812A (zh) * 2015-11-12 2017-05-24 江苏豪森药业集团有限公司 替诺福韦前药的制备和纯化方法
US10745428B2 (en) 2015-12-10 2020-08-18 Idenix Pharmaceuticals Llc Antiviral phosphodiamide prodrugs of tenofovir
US10450335B2 (en) 2015-12-15 2019-10-22 Merck Sharp & Dohme Corp. Antiviral oxime phosphoramide compounds
EP3411378B1 (en) 2016-02-02 2020-03-25 Sandoz AG Crystalline forms of tenofovir alafenamide monofumarate
CN107226826A (zh) * 2016-03-25 2017-10-03 江苏奥赛康药业股份有限公司 替诺福韦艾拉酚胺富马酸盐化合物及其药物组合物
WO2017203395A1 (en) * 2016-05-21 2017-11-30 Shilpa Medicare Limited Crystalline forms of tenofovir alafenamide hemi fumarate
CN109476689B (zh) * 2016-06-05 2021-09-03 上海诚妙医药科技有限公司 富马酸替诺福韦艾拉酚胺盐的新晶型、制备方法及其用途
MX369307B (es) 2016-08-19 2019-11-05 Gilead Sciences Inc Compuestos terapeuticos utiles para tratamiento profilactico o terapeutico de infeccion por virus de inmunodeficiencia humana.
US10449208B2 (en) 2016-08-25 2019-10-22 Merck Sharp & Dohme Corp. Antiviral prodrugs of tenofovir
CN107793451A (zh) * 2016-08-30 2018-03-13 江苏奥赛康药业股份有限公司 替诺福韦艾拉酚胺半富马酸盐化合物及其药物组合物
WO2018044822A1 (en) * 2016-08-31 2018-03-08 Viiv Healthcare Company Combinations and uses and treatments thereof
WO2018051250A1 (en) 2016-09-14 2018-03-22 Viiv Healthcare Company Combination comprising tenofovir alafenamide, bictegravir and 3tc
EP3532069A4 (en) 2016-10-26 2020-05-13 Merck Sharp & Dohme Corp. ARYL-AMIDE PHOSPHODIAMIDE COMPOUNDS ANTIVIRALS
CN108117570A (zh) * 2016-11-28 2018-06-05 正大天晴药业集团股份有限公司 一种替诺福韦艾拉酚胺半富马酸盐的结晶及其制备方法
CN108129514A (zh) * 2016-12-01 2018-06-08 北京美倍他药物研究有限公司 磷酸/膦酸衍生物的单一异构体及其医药用途
CN108070003A (zh) * 2016-12-02 2018-05-25 上海博志研新药物技术有限公司 替诺福韦艾拉酚胺半反丁烯二酸盐晶型及制备方法和应用
US10519159B2 (en) 2016-12-22 2019-12-31 Merck Sharp & Dohme Corp. Antiviral aliphatic ester prodrugs of tenofovir
CA3046029A1 (en) 2016-12-22 2018-06-28 Merck Sharp & Dohme Corp. Antiviral benzyl-amine phosphodiamide compounds
AU2017378959B2 (en) 2016-12-23 2021-09-09 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Nucleoside phosphate compound and preparation method and use thereof
WO2018115046A1 (en) 2016-12-23 2018-06-28 Sandoz Ag Crystalline solid forms of tenofovir alafenamide
TWI784370B (zh) * 2017-01-31 2022-11-21 美商基利科學股份有限公司 替諾福韋埃拉酚胺(tenofovir alafenamide)之晶型
WO2018153977A1 (en) 2017-02-24 2018-08-30 Hexal Ag Stable composition of tenofovir alafenamide
RU2659388C1 (ru) 2017-02-28 2018-07-02 Васильевич Иващенко Александр Нуклеотиды, включающие N-[(S)-1-циклобутоксикарбонил]фосфорамидатный фрагмент, их аналоги и их применение
CN108794530A (zh) * 2017-04-26 2018-11-13 上海医药工业研究院 一种替诺福韦丙酚酰胺盐晶型及其制备方法和用途
CN107445994A (zh) * 2017-05-31 2017-12-08 北京阜康仁生物制药科技有限公司 替诺福韦艾拉酚胺半富马酸盐新晶型
RU2662160C9 (ru) 2017-07-03 2018-10-22 Александрович Иващенко Андрей Комбинированный лекарственный препарат для терапии вирусных инфекций
AR112412A1 (es) 2017-08-17 2019-10-23 Gilead Sciences Inc Formas de sal de colina de un inhibidor de la cápside del vih
CN107522743A (zh) * 2017-09-30 2017-12-29 深圳科兴生物工程有限公司 一种半富马酸替诺福韦艾拉酚胺工业化连续生产方法
CN107865874A (zh) * 2017-10-23 2018-04-03 上海博悦生物科技有限公司 一种替诺福韦艾拉酚胺的药物组合物及其制备方法
EP3700573A1 (en) 2017-10-24 2020-09-02 Gilead Sciences, Inc. Methods of treating patients co-infected with a virus and tuberculosis
CN111372592A (zh) 2017-12-07 2020-07-03 埃默里大学 N4-羟基胞苷及衍生物和与其相关的抗病毒用途
US20200407382A1 (en) * 2017-12-30 2020-12-31 Cipla Limited Polymorphic forms of (9-[(r)-2-[[(s)-[[(s)-1-(isopropoxycarbonyl)ethyl]amino]phenoxy phosphinyl]methoxy]propyl] adenine and pharmaceutically acceptable salts thereof
AU2019221568B2 (en) 2018-02-15 2021-04-22 Gilead Sciences, Inc. Pyridine derivatives and their use for treating HIV infection
EP3752496B1 (en) 2018-02-16 2023-07-05 Gilead Sciences, Inc. Methods and intermediates for preparing a therapeutic compound useful in the treatment of retroviridae viral infection
CN108440596B (zh) * 2018-03-22 2020-07-03 科兴生物制药股份有限公司 一种半富马酸替诺福韦艾拉酚胺的新型制备工艺
JP2021528363A (ja) 2018-06-12 2021-10-21 シチュアン ケルン−バイオテック バイオファーマシューティカル カンパニー リミテッド ホスホンアミドエステル化合物、その塩、その関連する結晶体、その製造方法及びその使用
KR20210033492A (ko) 2018-07-16 2021-03-26 길리애드 사이언시즈, 인코포레이티드 Hiv의 치료를 위한 캡시드 억제제
WO2020018399A1 (en) 2018-07-19 2020-01-23 Merck Sharp & Dohme Corp. Phosphinic amide prodrugs of tenofovir
EP3852761A1 (en) 2018-09-19 2021-07-28 Gilead Sciences, Inc. Integrase inhibitors for the prevention of hiv
KR102054104B1 (ko) * 2019-04-30 2019-12-09 유니셀랩 주식회사 신규한 테노포비어 알라펜아미드 염 및 이의 제조방법
US20220257619A1 (en) 2019-07-18 2022-08-18 Gilead Sciences, Inc. Long-acting formulations of tenofovir alafenamide
CN110452268A (zh) * 2019-08-21 2019-11-15 天地恒一制药股份有限公司 一种丙酚替诺福韦半富马酸单晶的制备方法
CN114727999A (zh) 2019-11-26 2022-07-08 吉利德科学公司 用于预防hiv的衣壳抑制剂
WO2021165995A1 (en) 2020-02-20 2021-08-26 Cipla Limited Novel salts and/or co-crystals of tenofovir alafenamide
JP2023518433A (ja) 2020-03-20 2023-05-01 ギリアード サイエンシーズ， インコーポレイテッド ４’－ｃ－置換－２－ハロ－２’－デオキシアデノシンヌクレオシドのプロドラッグ並びにその製造法及び使用法
KR20210125298A (ko) 2020-04-08 2021-10-18 주식회사 파마코스텍 테노포비어 알라펜아미드 헤미타르트레이트의 신규한 제조방법
CN115996925A (zh) 2020-06-25 2023-04-21 吉利德科学公司 用于治疗hiv的衣壳抑制剂
KR20230107288A (ko) 2020-11-11 2023-07-14 길리애드 사이언시즈, 인코포레이티드 gp120 CD4 결합 부위-지향 항체를 이용한 요법에 감수성인 HIV 환자를 식별하는 방법
US11667656B2 (en) 2021-01-27 2023-06-06 Apotex Inc. Crystalline forms of Tenofovir alafenamide
KR20220141457A (ko) 2021-04-13 2022-10-20 경동제약 주식회사 신규 결정형의 테노포비어 알라펜아미드 말레산염 및 이를 포함하는 약제학적 조성물
KR20240117588A (ko) 2021-12-03 2024-08-01 길리애드 사이언시즈, 인코포레이티드 Hiv 바이러스 감염 치료용 화합물
WO2023102523A1 (en) 2021-12-03 2023-06-08 Gilead Sciences, Inc. Therapeutic compounds for hiv virus infection
EP4440702A1 (en) 2021-12-03 2024-10-09 Gilead Sciences, Inc. Therapeutic compounds for hiv virus infection
TWI843506B (zh) 2022-04-06 2024-05-21 美商基利科學股份有限公司 橋聯三環胺甲醯基吡啶酮化合物及其用途
WO2024006982A1 (en) 2022-07-01 2024-01-04 Gilead Sciences, Inc. Therapeutic compounds useful for the prophylactic or therapeutic treatment of an hiv virus infection
WO2024044477A1 (en) 2022-08-26 2024-02-29 Gilead Sciences, Inc. Dosing and scheduling regimen for broadly neutralizing antibodies
WO2024076915A1 (en) 2022-10-04 2024-04-11 Gilead Sciences, Inc. 4'-thionucleoside analogues and their pharmaceutical use

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7390791B2 (en) * 2000-07-21 2008-06-24 Gilead Sciences, Inc. Prodrugs of phosphonate nucleotide analogues
WO2008143500A1 (en) * 2007-05-22 2008-11-27 Ultimorphix Technologies B.V. Tenofovir disoproxil hemi-fumaric acid co-crystal

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5302585A (en) * 1990-04-20 1994-04-12 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Use of chiral 2-(phosphonomethoxy)propyl guanines as antiviral agents
EP0481214B1 (en) 1990-09-14 1998-06-24 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Prodrugs of phosphonates
US5798340A (en) 1993-09-17 1998-08-25 Gilead Sciences, Inc. Nucleotide analogs
US5468768A (en) 1994-01-06 1995-11-21 Bristol-Myers Squibb Company Antimigraine derivatives of indolylcycloalkanylamines
US5922695A (en) 1996-07-26 1999-07-13 Gilead Sciences, Inc. Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability
JP4033494B2 (ja) 1996-07-26 2008-01-16 ギリヤド サイエンシーズ， インコーポレイテッド ヌクレオチドアナログ
ES2198003T3 (es) 1996-07-26 2004-01-16 Gilead Sciences, Inc. Analogos de nucleotidos.
BR9811045A (pt) 1997-07-25 2000-08-22 Gilead Sciences Inc Composição de análogo de nucleotìdeo e processo de sìntese
TWI275392B (en) 2002-04-08 2007-03-11 Bristol Myers Squibb Co Low dose liquid entecavir formulations and use
US7642277B2 (en) 2002-12-04 2010-01-05 Boehringer Ingelheim International Gmbh Non-nucleoside reverse transcriptase inhibitors
JP2004288898A (ja) * 2003-03-24 2004-10-14 Canon Inc 太陽電池モジュールの製造方法
ECSP045074A (es) 2004-04-22 2004-05-28 Inhibidores hidroxipirimidinona carboxamida n-sustituida de integrasa de vih
JP4629104B2 (ja) 2004-05-21 2011-02-09 日本たばこ産業株式会社 ４−オキソキノリン誘導体および抗ｈｉｖ剤を含む併用剤
WO2007013086A1 (en) 2005-07-26 2007-02-01 Hetero Drugs Limited Novel polymorphs of tenofovir disoproxil fumarate
EP2049506B2 (en) 2006-07-07 2024-05-08 Gilead Sciences, Inc. Modulators of pharmacokinetic properties of therapeutics
ES2532502T3 (es) * 2006-07-12 2015-03-27 Mylan Laboratories Limited Proceso para la preparación de tenofovir
LT2487166T (lt) 2007-02-23 2016-11-10 Gilead Sciences, Inc. Terapinių agentų farmakokinetinių savybių moduliatoriai
SG190618A1 (en) 2008-05-02 2013-06-28 Gilead Sciences Inc The use of solid carrier particles to improve the processability of a pharmaceutical agent
SG10201706215UA (en) 2009-02-06 2017-08-30 Gilead Sciences Inc Tablets for combination therapy
US7973013B2 (en) 2009-09-21 2011-07-05 Gilead Sciences, Inc. 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment
ME01980B (me) 2010-11-19 2015-05-20 Gilead Sciences Inc Terapeutske kompozicije koje sadrže rilpivirin hcl i tenofovir dizoproksil fumarat
US8754065B2 (en) 2011-08-16 2014-06-17 Gilead Sciences, Inc. Tenofovir alafenamide hemifumarate
CN107266498B (zh) 2011-10-07 2023-10-03 吉利德科学公司 制备抗病毒核苷酸类似物的方法
KR20140119177A (ko) 2012-02-03 2014-10-08 길리애드 사이언시즈, 인코포레이티드 바이러스 감염의 치료에 사용하기 위한 테노포비르 알라페나미드 헤미푸마레이트 및 코비시스타트를 포함하는 조합 요법

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7390791B2 (en) * 2000-07-21 2008-06-24 Gilead Sciences, Inc. Prodrugs of phosphonate nucleotide analogues
US7803788B2 (en) * 2000-07-21 2010-09-28 Gilead Sciences, Inc. Prodrugs of phosphonate nucoleotide analogues
WO2008143500A1 (en) * 2007-05-22 2008-11-27 Ultimorphix Technologies B.V. Tenofovir disoproxil hemi-fumaric acid co-crystal

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Tenofovir alafenamide. WikipediA, The Free Encyclopedia. regăsit în Internet la 2016.10.03, url: https://en.wikipedia.org/wiki/Tenofovir_alafenamide *

Also Published As

Publication number Publication date
PL2744810T3 (pl) 2017-04-28
NZ620421A (en) 2015-05-29
JP6280162B2 (ja) 2018-02-14
JP2016169228A (ja) 2016-09-23
US8754065B2 (en) 2014-06-17
HRP20161696T4 (hr) 2023-10-13
DK2744810T3 (en) 2016-12-05
ES2608871T3 (es) 2017-04-17
EA201490208A1 (ru) 2014-06-30
CR20140072A (es) 2014-06-19
HK1199026A1 (en) 2015-06-19
UY34262A (es) 2013-04-05
LT2744810T (lt) 2016-11-25
MA35350B1 (fr) 2014-08-01
RS55353B2 (sr) 2023-11-30
AP2014007437A0 (en) 2014-02-28
CY1118385T1 (el) 2017-06-28
IL240649A0 (en) 2015-09-24
MX336627B (es) 2016-01-26
UA115311C2 (uk) 2017-10-25
CN110343135A (zh) 2019-10-18
WO2013025788A1 (en) 2013-02-21
PL2744810T5 (pl) 2024-02-05
IL230949A (en) 2015-09-24
MX2014001549A (es) 2014-02-27
SI2744810T1 (sl) 2017-01-31
EP3070088A1 (en) 2016-09-21
IN2014DN01012A (ro) 2015-05-15
US9296769B2 (en) 2016-03-29
AR087546A1 (es) 2014-04-03
ZA201400582B (en) 2017-11-29
EA027768B1 (ru) 2017-08-31
AP3639A (en) 2016-03-13
JP2014528924A (ja) 2014-10-30
AU2012296622C1 (en) 2017-02-16
JP2018065870A (ja) 2018-04-26
US20130065856A1 (en) 2013-03-14
ECSP14013206A (es) 2014-03-31
JP2015038149A (ja) 2015-02-26
TWI516499B (zh) 2016-01-11
CA2845553C (en) 2019-05-28
SMT201600476B (it) 2017-03-08
JP5651275B2 (ja) 2015-01-07
AU2012296622B2 (en) 2014-09-11
EP3831832A1 (en) 2021-06-09
AU2012296622A1 (en) 2013-05-09
MD20140011A2 (ro) 2014-05-31
SI2744810T2 (sl) 2023-11-30
HRP20161696T1 (hr) 2017-02-24
ES2608871T5 (es) 2024-04-04
SG2014011548A (en) 2014-09-26
EP2744810A1 (en) 2014-06-25
EP2744810B2 (en) 2023-09-13
ME02612B (me) 2017-06-20
EP2744810B1 (en) 2016-10-05
FI2744810T4 (fi) 2023-11-22
PE20141328A1 (es) 2014-10-04
RS55353B1 (sr) 2017-03-31
US20140187773A1 (en) 2014-07-03
CL2014000370A1 (es) 2014-09-05
KR101612642B1 (ko) 2016-04-14
KR20140054068A (ko) 2014-05-08
PT2744810T (pt) 2016-11-04
IL230949A0 (en) 2014-03-31
MD4508B1 (ro) 2017-08-31
CA2845553A1 (en) 2013-02-21
JP2020040972A (ja) 2020-03-19
DK2744810T4 (da) 2023-11-20
JP5956537B2 (ja) 2016-07-27
BR112014003420A2 (pt) 2017-03-01
BR112014003420B1 (pt) 2021-07-20
CO6880063A2 (es) 2014-02-28
CN103732594A (zh) 2014-04-16
TW201321396A (zh) 2013-06-01
HUE031253T2 (en) 2017-07-28

Similar Documents

Publication Publication Date Title
MD4508B1 (ro) Hemifumarat de tenofovir alafenamidă şi utilizările sale medicale
EA201491287A1 (ru) Комбинированная терапия, включающая тенофовир алафенамида гемифумарат и кобицистат, для применения для лечения вирусных инфекций
MY179392A (en) Pyrrolo[3,2-d]pyrimidine derivatives for the treatment of viral infections and other diseases
PH12014501258A1 (en) Pyrazolopyridine derivatives, preparation process therefor and therapeutic use thereof
MY173422A (en) Purine derivatives for the treatment of viral infections
PH12015500713A1 (en) Acylaminopyrimidine derivatives for the treatment of viral infections and further diseases
MY164274A (en) Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof
AU2012358805A8 (en) Pyrazolo[1,5-a]pyrimidines as antiviral agents
UA110473C2 (uk) Спосіб лікування раку за допомогою пухлиноасоційованого антигену, отриманого із цикліну d1
IN2014MU00118A (ro)
IN2013MU01967A (ro)
GB201209587D0 (en) Therapeutic compounds
BR112013024809A2 (pt) tratamento para infecção com vírus de hepatite b sozinho ou em combinação com vírus de hepatite delta e doenças do fígado associadas
MX340607B (es) Moduladores de la fosfodiesterasa 10 (pde 10).
MX2015011387A (es) Indolo[2,3-b]quinoxalina antiviral.
TN2013000146A1 (en) Salt(s) of 7-cyclopentyl-2 -(5-piperazin-1-yl-pyridin-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof
UA72117U (ru) Способ коррекции возрастных нарушений репродуктивной функции
TN2013000012A1 (en) New aminopyrazoloquinazolines
TN2011000610A1 (en) 2,4-diaminopyrimidines for the treatment of diseases characterised b y excessive or abnormal cell proliferation

Legal Events

Date Code Title Description
FG4A Patent for invention issued